Bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab in pleural mesothelioma
Jarushka Naidoo, Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University, shared an article by E. Felip on X:
“BEAT-MESO trial of 1L carbo/pem/bev +/- atezolizumab in pleural mesothelioma ESMO Open.
- 400pts
- did not meet it’s primary endpoint, mOS 20.5m v 18.1m p=0.14
- mPFS benefit 9.2 v 7.6m, p=0.0021
- OS HR 0.51 for non-epith
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial.
Authors: E. Felip, et al.
Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials. She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023